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The placement of ureteral stent (UrSt) at kidney transplantation reduces major urological complications but increases the risk for
developing nephropathy from the BK virus. It is unclear whether UrSt placement increases nephropathy risk by increasing risk of
precursor viral replication or by other mechanisms. We retrospectively investigated whether UrSt placement increased the risk for
developing BK Viremia (BKVM) in adult and pediatric kidney transplants performed at the University of Florida between July 1,
2007, and December 31, 2010. In this period all recipients underwent prospective BKV PCR monitoring and were maintained on
similar immunosuppression. Stent placement or not was based on surgeon preference. In 621 transplants, UrSt were placed in 295
(47.5%). BKVM was seen in 22% versus 16% without UrSt (𝑃 = 0.05). In multivariate analyses, adjusting for multiple transplant
covariates, only UrSt placement remained significantly associated with BKVM (𝑃 = 0.04). UrSt placement significantly increased
the risk for BKVM. Routine UrSt placement needs to be revaluated, since benefits may be negated by the need for more BK PCR
testing and potential for graft survival-affecting nephritis.
1. Introduction
BK virus (BKV) was first isolated in 1971 from the urine
of a Sudanese renal transplant recipient who presented with
ureteral stenosis [1]. Years later, a new era in the study of BKV
began when BK nephropathy (BKN) was diagnosed by a
needle biopsy in a renal transplant (RTx) recipient suspected
of having acute rejection [2]. In the following years, addi-
tional cases were reported from kidney transplant centers
worldwide [3–5]. In nonimmunosuppressed hosts, BKV
infection remains latent and asymptomatic in uroepithelial
cells, though a fraction of asymptomatic seropositive subjects
shed virus into the urine [6]. In states of immunosuppression,
such as after kidney transplantation, BKV is reactivated and
infection can progress from viruria to viremia, followed
by nephropathy [7]. Efforts to eradicate this problem have
included the identification of risk factors, early detection of
BK viruria (BKVU) and BK viremia (BKVM) through serial
PCR screening, early diagnostic biopsy for allograft dysfunc-
tion,minimization of immunosuppression for biopsy-proven
BKN, and the employment of pharmacotherapy [8].
Risk factors for BKV infection include a higher degree of
human leukocyte antigen mismatch, pediatric status, aggres-
sive immunosuppressive regimen, and transplant ureteral
stent use [9]. The role of stents is controversial. In two prior
single center adult studies, the placement of ureteral stent
(UrSt) at the time of kidney transplant was associated with
4-fold increase in the risk for developing BKVN [10, 11].
Our previous pediatric study also showed a 4-fold higher
risk, but this result did not reach statistical significance due
to limited single center sample size [12]. In this era, the
precursor viral replication stages BK viremia (BKVM) and
BK viruria (BKVU) were not monitored. It was unclear from
these studies whether the increased BK virus nephropathy
(BKVN) riskwithUrSt placementwas secondary to increased
likelihood of viral replication or due to other factors unrelated
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to, or after, replication initiation. Two studies reported an
increased risk in the precursor viral replication stage BKVM
with UrSt placement at kidney transplant. In both studies,
BKVU was not assessed [13, 14]. A twelve-month prospective
multicenter study that randomized renal transplant patients
to cyclosporine or tacrolimus showed that BKV viremia
increased in recipients with any of: higher corticosteroids,
using tacrolimus compared to cyclosporine, older age and
male gender at month 12 post-transplant [15].
Diagnosing a direct effect of UrSt placement is difficult
since by the time there is a clinical correlation such as acute
renal failure, hydronephrosis, and ureteral stenosis there is
so much fibrosis that BK is not evident. Animal studies have
confirmed this [16].
After our adult and pediatric kidney transplant programs
instituted a universal BKV serum screening protocol, our
practice has been to reduce immunosuppression at time of
BK viremia. This has led to a change in the natural history
of BKV infection, with nephropathy much less frequent but
viruria and viremia commonly detected.
The purpose of this study was to determine the
association between transplant UrSt placement and both
BKVM/BKVU in a larger group of recipients at a center
that performs a large number of adult and pediatric kidney
transplants.We report the largest series to date demonstrating
the relationship between transplant ureteral stenting and
early stages of BKV infection.
2. Methods
After approval from the Shands Hospital at University of
Florida Institutional Review Board, we conducted a retro-
spective secondary data analysis of all eligible adult and pedi-
atric renal transplants conducted at our institution between
July 1, 2007, and December 31, 2010. All eligible subjects
had to have at least 15 days of graft survival and at least 12
months of followup; otherwise those caseswere censored out.
At our center, all ureteroneocystostomies during the study
time period were performed by extravesical (Lich-Gregoir)
technique. All indwelling stents placed were 6-French 12 cm
double-J type. All transplants were performed by four sur-
geons in which certain surgeons almost always stented,
whereas others never stented, and that choice of surgeon was
arbitrary. Transplant ureteral stents were removed 6–8 weeks
following transplantation. We extracted data on recipient
demographics (age, sex, race, and primary diagnosis), donor
demographics (age, sex, and race), donor source (living or
deceased), transplant characteristics (ureteral stent or not,
PRA, HLA mismatch, ischemia times, and DGF or not), and
initial posttransplant immunosuppression.
During this period, immunosuppressionmedication con-
sisted of induction with basiliximab (20mg on days 0
and 3) or rabbit anti-thymocyte globulin (Thymoglobu-
lin, Genzyme, Cambridge, Massachusetts, USA; 3 doses of
1.5mg/kg/dose for high risk patients). Maintenance medica-
tion included prednisone 1mg/kg/day, postoperatively, which
will be tapered slowly over time (steroids beyond the first
week were reserved for specific situations in pediatric recipi-
ents), calcineurin inhibitor (tacrolimus or cyclosporine) with
the dosing adjusted according to the 12-hour trough level,
and mycophenolate mofetil (MMF) 2 g/day for Caucasians
or 3 g/day for African-Americans (AA) recipients. Pediatric
doses for MMF were 600mg/m2 divided bid standard pedi-
atric dose for non-AA children or 750mg/m2 divided bid
for AA children. In case mycophenolate sodium was used,
the dose was 1440mg/day divided bid (400mg/m2 for pedi-
atric dose). Both mycophenolate mofetil and mycophenolate
sodium are lumped and abbreviated as MMF in this report.
Delayed graft function was defined as hemodialysis within 1
week after kidney transplant.
Acute rejection was defined as biopsy-proven rejec-
tion. Acute cellular rejection was treated with intravenous
(IV) methylprednisolone or rabbit anti-thymocyte globulin
(ATG) depending on the severity. On the other hand, anti-
body mediated rejection was treated with plasmapheresis ±
IV methylprednisolone.
Surgical complications assessed included urinary leak-
age defined as accumulation of urine around the graft
and required Foleys catheter insertion with percutaneous
nephrostomy, urethral obstruction defined as impairment of
graft functionwith hydronephrosis, or pelvicaliceal dilatation
requiring percutaneous nephrostomy insertion or ureteral
operation.
2.1. Polyomavirus BK Viremia and Viruria Screening Protocol.
Beginning one month after transplantation, all renal trans-
plant recipients underwent monthly serum BK polymerase
chain reaction (PCR) measurement. Screening for BKV in
blood and urine was done monthly for the first year. All
PCR assays were performed at Shands Hospital Clinical
Laboratories. According to our lab, ≥500 copies/mL indicates
viremia and ≥4000 indicates viruria. Significant viremia, at
which point we reduced immunosuppression, was generally
at ≥5000 copies/mL through the time period of this study.
Confirmation of BKVM was defined by detection of BKV
PCR in plasma on 2 consecutive positive plasma samples
within 2 weeks. The diagnosis of nephropathy (BKVN) was
made by typical histological demonstration of BKV within
tissue (nuclear positivity of epithelial cells by BKV-specific in
situ hybridization or immunostaining for BKVusing amouse
anti-BKV large T antigen monoclonal antibody) and organ
damage (interstitial infiltrate or elevated serum creatinine).
In many patients where BKVMwas confirmed, reduction
of immunosuppression was usually initiated by 50% dose
reduction ofMMFandprednisone; persistent BKVMwithout
impairment of graft function prompted discontinuation of
MMF ± tapering of the dose of calcineurin inhibitor. Renal
biopsy was performed in any patient with impairment of graft
functionwith starting anti-BK therapy including leflunomide
or cidofovir for confirmed BKVN.
2.2. Statistical Analysis. The patients’ demographic and lab-
oratory values were compared between the stent and no-
stent recipients. Results are expressed as proportion (%) or
mean (standard deviation; SD). Analyses were performed
with chi-square testing for categorical variables (Fisher’s
exact test used for violations of Cochran’s assumptions) and
Student’s 𝑡-test for continuous variables (Mann-Whitney test
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was used for nonnormally distributed variables), respectively.
Variables assessed in the stent and nonstent groups included
recipient age group (<18, 18–50, or >50 years), recipient
gender and race, donor source (living or deceased), cold
ischemia time if deceased donor (<12, 12–24, or >24 hours),
graft function (immediate or delayed), and induction agent
(basiliximab versus Thymoglobulin). Statistical significance
for univariate comparisons was defined as 𝑃 < 0.05.
Multivariate stepwise logistic regression models were fitted
to study the adjusted relationship between UrSt use and
the development of the outcome variables BKVM or BKVU
by 12 months after transplant, the models including several
covariates with 𝑃 values < 0.10 on univariate testing, and
induction agent, given the association our group has previ-
ously demonstrated between Thymoglobulin induction and
subsequent BKV nephropathy [17]. Deceased donor source,
higher cold ischemia time, and delayed graft function were
strongly associatedwith each other, so only the latter two vari-
ables, more direct indicators of tissue injury, were included in
the fitted models. Given the unexpected associations seen in
our study group between stent placement and graft function,
we also included an interaction term betweenUrSt placement
and graft function in our multivariate models. All statistical
analyses were performed using SAS software version 9.3
(Cary, NC, USA).
3. Results
A total of 640 kidney transplants were performed at the
University of Florida/Shands Hospital between July 1, 2007,
and December 31, 2010. The placement of ureteral stents
or not was confirmed in 621/640 (97%). Thus we excluded
19 transplants, leaving a final study group of 621. Of these,
295/621 (47.5%) received a ureteral stent at time of kidney
transplant. A total of 3283 urine samples with 583 positive
tests (17.7%) and 8332 plasma samples with 934 positive tests
(11.2%) were obtained from all the visits between months 1
and 12 after transplant.
The demographic parameters were not significantly dif-
ferent in the two groups (stent or no stent) with respect to
recipient age, gender, ethnicity, or type of induction therapy
(Table 1). Stents were inserted more frequently among recip-
ients with a living donor transplant and low cold ischemia
times, or immediate graft function, contrary to expectations
[18].
When we performed a separate analysis restricting the
study population to adults only (𝑛 = 581), the demographics
did not change with respect to patterns seen in gender,
ethnicity, donor source, or cold ischemia times. The only
pattern changes were that proportion of induction agent
(Thymoglobulin versus basiliximab) met statistical signifi-
cance for difference, 60/45% in stent group versus 40/55% in
nonstent group,𝑃 = 0.01. Immediate graft function, higher in
the stented group, became borderline significant (𝑃 = 0.05).
Further analyses were thus performed on the entire study
group.
In univariate analysis models, ureteral stent placement
was significantly associated with higher rates of BKVM and
BKVU within the first year after transplantation (Table 1).
Table 1: Study group demographics based on stent placement.
Demographic variables Stent placed No stent
𝑃 value
Total number 621 295 (47.5%) 326 (52.5%)
Age group 0.06
<18 yr 17 (6%) 15 (5%)
18–50 yr 139 (47%) 124 (39%)
>51 yr 139 (47%) 187 (75%)
Donor source 0.01
Deceased donor 231 (80%) 300 (92%)
Living donor 64 (20%) 26 (8%)
Gender 0.87
Male 190 (64%) 208 (64%)
Female 105 (36%) 118 (36%)
Race 0.59
White 171 (58%) 199 (61%)
African-American 99 (33%) 97 (30%)
Others 25 (8%) 30 (9%)
Induction 0.23
Thymoglobulin 81 (27%) 58 (18%)
Basiliximab 212 (72%) 262 (80%)
Missing 2 (0.7%) 6 (1.8%)
Cold ischemia time 0.02
<12 h 91 (31%) 58 (18%)
13–24 h 103 (35%) 113 (35%)
>24 h 99 (33%) 149 (45%)
Missing 2 (0.7) 6 (1.8%)
Graft function 0.02
Immediate 180 (61%) 166 (51%)
Delayed 112 (38%) 155 (47.5%)
Missing 3 (1%) 5 (1.5%)
BK viruria 75/250 (30.0%) 62/279 (22.2%) 0.04
137/529 (25.8%)
BK viremia 63/289 (21.8%) 52/317 (16.4%) 0.05
115/606 (19.0%)
Themedian onset for BKVMwas 111 days (range 3–361) (75%
of cases were in the first 6months after transplantation) while
the median for BKVU after transplant was 128 days (range 5–
362) (72.2% of cases were in the first 6 months). Patient age,
gender, and ethnicity were not statistically significant factors
in the development of BK infection. As expected based on
our study demographics, BKVMandBKVUrateswere higher
in recipient with IGF or with lower cold ischemia time (21%
versus 32%, 𝑃 = 0.03, and 16% versus 22%, 𝑃 = 0.04),
respectively.
In the multivariate model for BKVM, adjusting for
multiple covariates as shown in Table 2, only UrSt placement
remained as a significant variable (𝑃 = 0.04). Similarly, we
includedBKVU in themultivariate adjustedmodel, and again
only UrSt placement remained as a significant variable (𝑃 =
0.04, Table 3).
The cutoff values currently used by many centers as
significant enough to warrant intervention have changed
over time. We ran additional analyses and determined that
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Table 2: Logistic model for viremia.
Predictor variable 𝑃 value Odds ratio (95% CI)
Ureteral stent 0.04 1.55 (1.04–2.38)
Age group 0.16 0.46 (0.14–1.55)
Gender 0.43 0.87 (0.55–1.36)
Cold ischemia time 0.42 1.62 (0.89–2.86)
Induction medication 0.82 0.82 (0.47–1.44)
Graft function 0.76 0.54 (0.31–0.98)
Table 3: Logistic model for viruria.
Predictor variable 𝑃 value Odds ratio (95% CI)
Ureteral stent 0.04 1.67 (1.03–2.81)
Age group 0.13 1.39 (0.95–2.14)
Gender 0.49 1.15 (0.76–1.76)
Cold ischemia time 0.82 0.94 (0.55–1.61)
Induction medication 0.91 1.12 (0.66–1.92)
Graft function 0.41 0.65 (0.32–1.34)
viremia >10,000 copies/mL was seen in 465 samples and
viruria >10 million copies/mL was seen in 267 of the samples
(approximately half of the total positives in each). At these
cutoffs, none of the covariates identified as being signif-
icant previously retained significance in the univariate or
multivariate analyses. However, our original hypothesis was
that ureteral stent placement would increase the risk for any
viremia or viruria, which was confirmed.
4. Discussion
The placement of a ureteral stent at time of kidney trans-
plant offers the advantages of reduced stenosis, obstruction,
or leakage across the newly created anastomosis between
donor ureter and recipient urinary bladder. Conversely, the
disadvantages of ureteral stent placement include possible
migration of the stent, increased risk of early urinary tract
infections, and the need for a separate urological procedure
to remove the stent. In adults, many studies including two
randomized trials suggested benefit, while others did not [19–
27]. A meta-analysis by Wilson et al. showed that overall
the benefits of preventing major urological complications
exceeded the negatives from complications [23]. However,
these studies and meta-analysis were performed before the
association of stent placement with BK virus nephropathy
was known, perhaps altering the risk-benefit ratio [15]. More
recent single center analyses also looked at risk-benefit ratio
without considering the potential for BKV replication or
disease development [28]. In children, Bergmeijer et al.
showed in the early 1990s a significant reduction of urological
complications in stented versus nonstented children [29]. Ten
years later, French et al. found no significant difference in
both groups with overall lower urological complications than
in prior eras [30].
Studies in animal models have revealed biological reac-
tions to stent insertion in the form of epithelial destruction
with erosions, ulcerations of the transitional epithelium, and
inflammatory reactive changes within 6 weeks of stenting
the animals’ ureter [31–34]. Thus, the mechanical trauma
associated with stent placement may injure the uroepithe-
lium, allowing for latent BK virus to enter replicative phases.
Atencio et al., in a mouse polyoma model, found that an
injury was required for adult uroepithelial cells to be per-
missive for polyoma viral replication [33]. Other investigators
created various mathematical models of BK viral infection
dynamics and found that the model in which replication
starts at the kidney and reaches the urinary tract, followed by
bidirectional viral flux into both compartments, was themost
compatible with clinical cases [35]. Hence, conditions that
favor backwash vesicoureteral reflux, such as stenting, should
be important in the dynamics of BK infection pathogenesis.
Thus, clear pathophysiological mechanisms exist that make
the association between stent placement and BKV infection
plausible.
In this large, single center study, we observed BKVM
in 19% and BKVU in 26% of the transplants, consistent
with previous reports in the literature [13, 36]. Although the
nonstented group had more patients receiving a graft from
deceased donor and had higher ischemic times, the stent
group still had a significantly higher adjusted risk for BKVM
and BKVU. Multivariate analysis showed that ureteral stent
placement was the only factor associated with an increase in
the incidence of both BKVM and BKVU.
The major strength of this study is the large size of
the cohort, the availability of detailed viral replication data
both in the urine and blood, and a mix of pediatric and
adults transplants. Notably, the prior studies associating
stent placement with full BKVN comprised 200 [10] and
66 patients [11]. In conjunction with the prior associations
with nephropathy which was noted in the two prior studies
[10, 11], our results indicate that BKVN risk is therefore likely
secondary to initiation of viral replication by the ureteral stent
placement.
Prior studies associating stent placement with the pre-
cursor viremia stage comprised 186 [13] and 600 patients
[14]. Our study, with 621 patients, looked at BK viruria, a
precursor stage earlier to BK viremia, which was not done
by both previous studies, though the second study was from
our same institution, conducted independently by a separate
author group [14]. Our study also found and adjusted for
a significant association between immediate graft function
and UrSt placement that the previous studies did not report
and therefore they did not adjust for it in their multivariate
analyses. Similar to the finding of other studies, we did not
find any correlation between incidence of BKVM and the
length of UrSt placement [13, 14]. The lack of correlation
might indicate that the ureteral damage that occurs by UrSt
placement is not related to stent duration. Furthermore, we
did not find any correlation between induction antibody
medication and BKVM. Thymoglobulin use was associated
with BK in a UNOS database study [8], but dose details
are not known in national databases and we use only a
short 3-day induction, likely less than what others have used.
Similarly, most of our recipients received tacrolimus, MMF,
and prednisone, so it was not possible in our study to analyze
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if maintenance treatment has an effect on the risk of BKVM
between both groups.
The limitations of our study include the single center and
retrospective nonrandomized data collection. It is possible
that the surgeon’s decision to use a stent and the surgeon’s
competence may have depended on facing potential intra-
operative ureteric complications that cannot be ascertained
from chart review. In addition, regression analysis was used
to account for five known confounding variables, namely, age,
gender, ethnicity, induction type, and DGF, but other as yet
unknown variables may have influenced this relationship. In
our study, we found higher incidence of BKV infection in
recipients with IGF. The reason for this association is not
clear but we adjusted for it in our multivariate models. A ran-
domized controlled trial in a large prospective study group is
recommended to confirm our observations. Neither we nor
others have attempted to determine if BKV PCR monitoring
frequency or duration is altered by a finding of BK PCR pos-
itivity, the latter being more common after stent placement.
Our BKV screening protocol virtually eliminated early
graft loss due to BK infection in our program without the
use of an invasive allograft biopsy. In most of our BKV
infection cases, PCR screening for BKV in the urine and/or
blood allowed for early detection of the infection and with
early intervention, progression of BKV infection to BKN was
prevented. Ideally, these data are hypothesis-generating and
randomized studies of ureteral stenting or not at time of
kidney transplant are still needed to confirm such findings
but may become unrealistic in light of the low allograft loss
rates as many programs follow the guidelines for BK PCR
monitoring.
In summary, our study demonstrates, in a large adult and
pediatric population, that ureteral stent placement increases
the risk for early precursor viral replication stages of BK
virus allograft nephropathy in kidney transplantation. While
the natural history and progression to full nephropathy is
potentially modified by the use of frequent viral PCR mon-
itoring and immunosuppression adjustment, the increased
BKVM and BKVU incidence after ureteral stent placement
may have changed the risk-benefit ratio that so far points to
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